– Activate Injections, Inc. (“Activate”)a leader in wearable drug delivery technologies, today announced an expanded partnership with rock.
– The collaboration leverages Enable’s expertise in the field enFuse® Platform accelerate the development and commercialization of innovative treatment options.
EnFuse Technology: Revolutionizing Medication Delivery
The enFuse platform is a revolutionary wearable device designed to:
- Subcutaneous administration of large volumes: Unlike traditional methods, enFuse delivers large volumes of medication subcutaneously, eliminating the need for intravenous (IV) administration.
- Simplified treatment experience: enFuse offers patients a simpler and potentially more comfortable injection experience than IV treatments.
Roche obtains exclusive rights to combine enFuse with specific molecules
Under the terms of the agreement, Roche receives an exclusive global license to develop and commercialize combinations of enFuse technology with specific drugs from its portfolio. Enable will assume responsibility for the clinical and commercial manufacturing and supply of the enFuse system.
“IV infusions can be inconvenient and time-consuming for both patients and providers. This is especially true when treating chronic disorders, which require longer-term treatment and frequent trips to the clinic,” said Mike Hooven, Chairman and CEO of Enable Injections. “enFuse was designed to overcome IV infusion shortcomings through fast, simple and convenient delivery, bringing efficiency and value to the entire spectrum of healthcare, including patients, providers, and payers, with the ability for at home self-administration.”
